Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 2/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17432212 | 0.92 | WDR5 (0.45) | HRH3MAPTL3MBTL1CHKACYP2A13 | |
| SCHEMBL18879716 | 0.91 | CHKA (0.50) | MAPTCHKASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18876443 | 0.85 | HRH3 (0.51) | HRH3MAPTCYP2A13SMN1; SMN2 | |
| SCHEMBL17431925 | 0.85 | ALDH1A1 (0.47) | MAPTCHKASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18970042 | 0.84 | MAPT (0.43) | HRH3MAPTCYP2A13SMN1; SMN2NCF1 | |
| SCHEMBL18876445 | 0.82 | HRH3 (0.46) | HRH3MAPTCHKAKDM4EALDH1A1 | |
| SCHEMBL18970043 | 0.81 | ALDH1A1 (0.48) | MAPTCHKASMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL17422312 | 0.81 | HRH3 (0.42) | HRH3MAPTCYP2A13SMN1; SMN2ALDH1A1 | |
| SCHEMBL17432251 | 0.81 | CHKA (0.45) | MAPTCHKAKDM4EALDH1A1NCF1 | |
| SCHEMBL17422227 | 0.80 | SMN1; SMN2 (0.45) | HRH3MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2019-01-15 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | HRH3 3759/4885MAPT 44/4885L3MBTL1 3531/4885 |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | TNKS1BP1, TPI1, TPMT | HRH3 3441/4885MAPT 37/4885L3MBTL1 4048/4885 |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TPI1, TBKBP1 | HRH3 3679/4885MAPT 46/4885L3MBTL1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.